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We readwith great interest the recent paper by Yilmaz et al.1 on
the epidemiology of Crimean-Congo hemorrhagic fever (CCHF) in
Turkey. We have recently experienced a birth of a baby born to a
mother with CCHF and wish to discuss the effect of the virus on
pregnancy and the fetus.
The transmission of CCHF to humans is through tick bite or by
direct contact with blood or tissues of infected humans or viremic
animals.2 Nosocomial transmission and horizontal transmission of
the infection from amother to her child have also been reported.3,4
Vertical transmission during pregnancy is theoretically possible,
but effects of maternal disease on the fetus have not been reported
to date. We report herein a healthy newborn with a maternal
history of CCHF and aim to discuss transplacental transmission of
the virus.
A 2300 g male infant was born at 37 weeks of gestation to a 29-
year-old mother. The pregnancy was uneventful up until 30 weeks
of gestation, when the mother experienced malaise and fever
(39 8C). Although the mother had a history of recent travel to
C¸ankırı, a city where CCHF is endemic, no evidence of tick bite was
noted. Laboratory investigation revealed pancytopenia with a
white blood cell count of 2.9  109/l, hemoglobin 8.5 g/dl, platelet
count 75  109/l, and elevated liver enzymes, creatine phospho-
kinase, and lactate dehydrogenase. The activated partial throm-
boplastin time was 45 s. Reverse transcriptase-polymerase chain
reaction (RT-PCR) for CCHF virus was positive. The mother was
discharged on day 8 of hospitalization with totally normal clinical
and laboratory ﬁndings.
The baby was born small for gestational age, but all other
ﬁndings were normal. He was admitted to our neonatal intensive
care unit (NICU) and isolated because of the maternal history of
CCHF. He did not develop any signs or symptoms of CCHF during
his one week follow-up in the NICU. Hematological and
biochemical tests were normal and RT-PCR for CCHF virus was
negative.
There are no data in the literature about the fetal effects of
maternal CCHF acquired at any time during pregnancy. In the
present case, the mother had acquired the disease at 30 weeks of
gestation, just 7 weeks before delivery, and there was no evidence
of transplacental transmission. The timing of the infection during
pregnancy is important for disease manifestations. Viral infections
acquired in the ﬁrst trimester usually lead to abortion or1201-9712/$36.00 – see front matter  2009 International Society for Infectious Disea
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viral infection leads to disease manifestations in the neonatal
period or later in infancy. The timing of the infection might have
been a protective factor for the fetus in our case. To the best of our
knowledge this is the ﬁrst case with maternal CCHF during
pregnancy.
One thousand eight hundred and twenty CCHF cases were
diagnosed between 2002 and 2007 in Turkey and the crude fatality
rate has been calculated to be 5%.1 This is much lower than
previously reported, with ﬁgures of 30–50% from Africa, Asia and
Europe.5 This may be related to the lower virulence of the virus
circulating in Turkey. Our case’s mother had a benign disease
course and recovered completely in a week. We believe that the
severity of the maternal disease in addition to the lower virulence
of the virus circulating in Turkey may be important factors
affecting transmission to the fetus.
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